Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML1400

Sigma-Aldrich

AEE788

≥98% (HPLC)

Synonym(s):

6-{4-[(4-Ethyl-1-piperazinyl)methyl]phenyl}-N-[(1R)-1-phenylethyl]-1H-pyrrolo[2,3-d]pyrimidin-4-amine, CID 10297043, NVP-AEE 788, [6-[4-[(4-Ethylpiperazin-1-yl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R)-1-phenylethyl)amine

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C27H32N6
CAS Number:
497839-62-0
Molecular Weight:
440.58
UNSPSC Code:
12352200
PubChem Substance ID:
329825848
NACRES:
NA.77
Pricing and availability is not currently available.

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

H2O: 10 mg/mL, clear

storage temp.

−20°C

SMILES string

C[C@H](C1=CC=CC=C1)NC2=C3C(NC(C4=CC=C(CN5CCN(CC)CC5)C=C4)=C3)=NC=N2

InChI

1S/C27H32N6/c1-3-32-13-15-33(16-14-32)18-21-9-11-23(12-10-21)25-17-24-26(28-19-29-27(24)31-25)30-20(2)22-7-5-4-6-8-22/h4-12,17,19-20H,3,13-16,18H2,1-2H3,(H2,28,29,30,31)/t20-/m1/s1

InChI key

OONFNUWBHFSNBT-HXUWFJFHSA-N

Gene Information

human ... EGFR(1956) , ERBB2(2064) , FLT1(2321) , KDR(3791)

Biochem/physiol Actions

AEE788 is an orally available and potent dual family of human EGFR and VEGFR receptor tyrosine kinase inhibitor that exhibits potent antitumor and antiangiogenic activity.
AEE788 is an orally available and potent dual family of human EGFR and VEGFR receptor tyrosine kinase inhibitor.

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
095M4735V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Rintu Thomas et al.
International journal of molecular sciences, 20(10) (2019-05-28)
Inhibiting the tyrosine kinase activity of epidermal growth factor receptor (EGFR) using small molecule tyrosine kinase inhibitors (TKIs) is often ineffective in treating cancers harboring wild-type EGFR (wt-EGFR). TKIs are known to cause dimerization of EGFR without altering its expression

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service